Independent data review supports continuation of phase III programme with intravenous iclaprim
Arpida Ltd announced that it has received the recommendation from an independent Data and Safety Monitoring Board (DSMB) to continue the Phase III clinical trials for intravenous iclaprim for the indication complicated Skin and Skin Structure Infections (cSSSI). The DSMB made its recommendation after a planned review of clinical data from the ongoing ASSIST-1 (Arpida s Skin and skin Structure Infection STudies) trial. The DSMB reviewed data on approximately 40% of the total number of patients to be enrolled into ASSIST-1, the first of the two ASSIST trials, and concluded that there are no safety concerns that would justify changes to be made to the clinical study design for either trial.
The results are blinded to Arpida and will remain so until the trial is fully completed. The global Phase III ASSIST trials are designed to compare the efficacy and safety of iclaprim with that of market leader linezolid (marketed by Pfizer as Zyvox®). Both ASSIST-1 and ASSIST-2 are global, multicenter trials conducted in various countries in North America, Europe and the rest of the world. Arpida expects to complete ASSIST-1 before the end of 2006.
Most read news
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.